Dr Paul P. Doghramji: Prescribing Biosimilars in IBD

Paul P. Doghramji, MD, FAAFP, discusses whether he has begun to prescribe biosimilars for patients with inflammatory bowel disease.


Are you or any of your colleagues beginning to prescribe biosimilars?

I haven’t started prescribing biosimilars yet for these diseases. I tend to use brand names more than anything, but sometimes I’m forced to do it because of insurance constraints. As a general rule, we like to use a medication that’s come out by that specific pharma company in that brand name because we know exactly what we’re getting.